Cargando…
F-Box Protein FBXO22 Mediates Polyubiquitination and Degradation of CD147 to Reverse Cisplatin Resistance of Tumor Cells
Drug resistance remains a major clinical obstacle to successful treatment of cancer. As posttranslational modification is becoming widely recognized to affect the function of oncoproteins, targeting specific posttranslational protein modification provides an attractive strategy for anticancer drug d...
Autores principales: | Wu, Bo, Liu, Zhen-Yu, Cui, Jian, Yang, Xiang-Min, Jing, Lin, Zhou, Yang, Chen, Zhi-Nan, Jiang, Jian-Li |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5297841/ https://www.ncbi.nlm.nih.gov/pubmed/28117675 http://dx.doi.org/10.3390/ijms18010212 |
Ejemplares similares
-
F-box protein FBXO22 mediates polyubiquitination and degradation of KLF4 to promote hepatocellular carcinoma progression
por: Tian, Xin, et al.
Publicado: (2015) -
HSP90 promotes radioresistance of cervical cancer cells via reducing FBXO6‐mediated CD147 polyubiquitination
por: Song, Qi, et al.
Publicado: (2022) -
FBXO22 mediates polyubiquitination and inactivation of LKB1 to promote lung cancer cell growth
por: Zhu, Xiao-Na, et al.
Publicado: (2019) -
FBXO22 degrades nuclear PTEN to promote tumorigenesis
por: Ge, Meng-Kai, et al.
Publicado: (2020) -
The F‐box protein FBXO11 restrains hepatocellular carcinoma stemness via promotion of ubiquitin‐mediated degradation of Snail
por: Shao, Lijiang, et al.
Publicado: (2020)